FINWIRES · TerminalLIVE
FINWIRES

标普称,中东战争旷日持久将导致亚太地区银行信贷损失增加1800亿美元。

-- 标普全球评级周三发布报告称,在中东战争持续的负面情景下,未来两年亚太地区银行的信贷损失可能激增约1800亿美元。 在此情景下,2026年和2027年两年期信贷损失总额可能达到9100亿美元,而标普的基本情景预测为7300亿美元。 标普表示,在此情景下,信贷损失占贷款总额的比例上升将对越南、印尼和印度造成最大冲击。 在标普的基本情景下,由于银行对中东的直接风险敞口较低,间接风险敞口也可控,因此受战争的影响较小。 信贷分析师加文·冈宁表示,在负面情景下,银行可能会受到家庭、企业和政府部门的次生影响。 对航空、能源、化工和运输等易受影响的企业部门敞口较大的银行将受到更大的冲击。 然而,标普预计,在当前评级水平下,即使面临下行风险,银行的缓冲能力也足以应对。 在标普评级的该地区400多家金融机构中,92%的评级展望为稳定,仅有2.9%的评级展望为负面。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA